solid alexion eye pipelin includ ultomiri
trial treatment coronaviru
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
alexion pharmaceut land uniqu ultrarare-diseas
blockbust soliri expand reach
origin approv paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom ahu gener
myasthenia gravi gmg neuromyel optica
spectrum disord nmosd alexion provid
disease-modifi treatment avail indic give
firm substanti price power patient share
potenti expand new indic two drug
ultrarar diseas strensiq kanuma promis pipelin
well-posit retain lead statu rare-diseas market
special salesforc believ alexion
despit outsiz success soliri alexion come
turbul year expens acquisit metabol
indic investig aggress sell tactic
nearli complet manag turnov restructur
program believ alexion final side
seriou misstep execut previou manag
new leadership record larg unprov strong
launch soliri gmg approv ultomiri continu
effort bolster pipelin point new era beleagu
pipelin competit grow drug manufactur flock
lucr autoimmun market alexion first-mov statu
well ultomiri relat pipelin mitig risk
addit firm continu drive growth
identif new patient across globe alexion
special salesforc strong entrench patient
doctor rais barrier entri brand competitor
soliri high price draw question price pressur whether
polit motiv incit mount competit
howev volum growth label expans conveni
dose ultomiri alreadi cheaper soliri
help stave consider price headwind biosimilar
brand competitor encroach indic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria
neuromyel optica spectrum disord nmosd next-gener
ultomiri approv pnh ahu strensiq kanuma target
ultrarar metabol diseas alexion pipelin target rare diseas
high unmet need hematolog nephrolog metabol diseas neurolog
cardiolog area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
solid alexion eye pipelin includ
ultomiri trial treatment coronaviru may
narrow-moat alexion report first-quart earn
may follow previou day announc
agreement acquir portola billion total
revenu last year adjust oper
margin expans basi point compani
nice first quarter howev eye alexion plan
diversifi away relianc rare-diseas drug
soliri ultomiri far investor remain unimpress
share trade nearli discount
unchang fair valu estim per share
believ market overlook compani abil
hold share next-gener therapi well
manag put new guidanc includ modest
impact revenu coronaviru plan
tweak estim expect
materi valuat line manag new
guidanc also plan lower expect
oper expens primarili clinic
trial delay somewhat off-set increas
expens alexion plan conduct phase
trial test ultomiri treatment base
preclin preliminari clinic evid
patient opportun materi revenu
forecast point watch
soliri
ultomiri convers continu track well attain
paroxysm nocturn
hemoglobinuria key geographi expect similar
atyp hemolyt urem
syndrom two rare neurolog disord approv
look ahead rest year focus
earli data third quarter
glomerulopathi believ present potenti
lower fair valu estim
per share follow guidanc manag
fell expect top bottom
line main driver includ price volum
alexion key drug soliri ultomiri model
steadi revenu growth driven modest
patient growth pnh ahu dampen slightli
push convert patient ultomiri solid growth gmg
approv success roll-out nmosd
approv model single-digit price headwind
soliri ultomiri probability-weight
competitor entri start biosimilar entri
throughout explicit forecast
project assum substanti patient declin pnh
ahu due biosimilar slightli larger hit
outsid howev regulatori orphan drug
exclus newer launch gmg nmosd
also larger address patient popul bolster
alexion posit price headwind off-set volum
increas led gmg nmosd
pipelin contribut million
probability-adjust sale
candid earli stage posit trial readout
pipelin could provid upsid valuat
strensiq kanuma grow modestli throughout
forecast believ face competitor
given obscur indic result five-year
revenu compound-annual-growth-rate low-single-digit revenu
compound-annual-growth-rate despit continu increas
oper expens fund commerci
clinic strategi oper margin expand nice
end forecast thank growth
top line
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ultrarar rare diseas high unmet medic need
ultrarar paroxysm nocturn hemoglobinuria pnh
alexion blockbust drug soliri extend
reach ultrarar atyp hemolyt urem syndrom
ahu rare gener myasthenia gravi
gmg rare neuromyel optica spectrum
disord nmosd soliri patent
protect market exclus pnh ahu set
expir next five year orphan drug exclus
continu provid protect gmg nmosd
larger target popul still fit
compani focu rare life-threaten diseas
ultomiri approv pnh end ahu
offer conveni dose schedul
opportun maintain signific market share
addit patent protect market exclus strensiq
ultrarar hypophosphatasia kanuma
ultrarar lysosom acid lipas defici lal-d
launch pair alexion pipelin
candid rare indic provid diversif
alexion
treatment option
patient autoimmun metabol diseas
target compani drug pipelin
prognos caus diseas slightli differ
patient pnh ahu devast
uncontrol activ immun system specif
part call complement result chronic
destruct red blood cell lead blood clot
organ failur thirty-f percent pnh patient die within
five year ahu patient progress end-stag
renal diseas lal-d patient miss key
enzym critic metabol function case
compani long-term outcom hing factor
includ success convert patient soliri
ultomiri time subcutan version ultomiri
time competitor entri result believ
alexion face rather wide rang possibl outcom
give compani high uncertainti rate
bear case brand competitor biosimilar
larger impact alexion sale competitor
captur outsiz patient share base price safeti
efficaci case alexion face annual
double-digit price headwind ultomiri pipelin
failur result substanti revenu declin
fair valu estim per
bull case brand competitor fail reach approv
impact biosimilar mute thank ultomiri
attract dose schedul price model smaller
price headwind compani see solid revenu growth
case fair valu estim
per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
onset diseas start birth close
birth patient die organ failur within year gmg
nmosd character unpredict relaps
includ life-threaten symptom like respiratori
failur gmg nmosd well blind
paralysi nmosd access alexion drug
matter life death alexion treat
diagnos popul pnh ahu predict
similar dynam gmg nmosd well
compani focu rare ultrarar diseas well
unmatch efficaci soliri allow alexion
maintain substanti price power line rare-
ultrarare-diseas drug soliri come high price
tag estim annual list net price soliri
pnh
indic meanwhil strensiq
kanuma price nontrivi net annual sum
per patient respect
per-pati cost extrem high overal burden
countri healthcar system small sinc number
affect patient extrem limit drug
clear disease-modifi benefit help justifi high price
facilit reimburs payer public
privat dynam allow alexion maintain
narrow band ex-u price
compani proactiv price ultomiri discount
soliri facilit patient convers new drug
list net price
indic strong patient convers crucial patient
share retent biosimilar competitor enter
pictur concern ultomiri price
discount absolut term drug still fetch
hefti figur even rare-diseas standard also first
year ultomiri includ seri initi load dose
actual put first year ultomiri roughli
premium soliri pnh dynam allow
compani captur valu crucial prebiosimilar
year patient convert maintain drug
cheaper long run
potenti brand competitor hurdl high bar
efficaci conveni establish soliri
ultomiri face signific barrier market entri
given alexion salesforc network patient
doctor mani alexion potenti brand competitor
inject self-administ alexion also
work subcutan form ultomiri
approv could enter market possibl sooner
believ alexion first-to-market statu soliri
strong efficaci ultomiri much conveni
dose schedul six seven infus per year versu
infus per year establish high barrier entri
even competitor succe reach regulatori
approv compet compani would face uphil
battl alexion global network patient
doctor well special salesforc
decad experi ultrarar rare diseas given
averag doctor never encount patient
one rare diseas career take
uniqu strategi identifi educ correct contact
soliri approv countri intang
asset gener alexion decade-plu global
experi rare autoimmun diseas easili
match competitor alexion launch gmg
testament compani experienc commerci
strategi compani nearli patient
roughli address patient estim
soliri less one year launch despit fact
gmg patient enrol competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
threat biosimilar loom label expans
believ alexion well-posit withstand
pressur competitor potenti entri earli
biosimilar like entri pnh
expand larger patient popul proactiv
price ultomiri discount offer conveni
dose soliri biosimilar would mean go back
doctor visit per year infus expect
reimburs issu ultomiri biosimilar
usual price discount origin drug
given ultomiri alreadi price discount
offer much conveni dose think like
alexion hold substanti share expect
pipelin ultomiri therapi includ intraven
form offer shorter infus time well weekli
biweekli monthli subcutan self-administ
inject form like bolster patient volum ward
signific ultomiri price headwind
pipelin competitor biosimilar entri pnh
like ahu gmg believ
patent-protect ultomiri label expans orphan
drug indic gmg nmosd help compani
retain moat intang asset support moat
weaken approach end patent protect
market exclus indic
look sever quantit qualit factor
consid moat trend return invest
capit econom profit steadili climb first
five year forecast recov larg
synageva acquisit howev soliri
patent expir signifi substanti weaken
alexion moat sourc intang asset compar
last sever year believ compani merit
neg moat trend wherea alexion narrow moat
cement clear patent protect think
forthcom like biosimilar hit price pressur
indic alexion competit posit
precari next five year compar past
believ strensiq kanuma alexion pipelin
off-set effect soliri biosimilar pipelin
prove promis new data would reconsid
moat trend note despit soliri patent expir
intang asset form compani substanti
experi identifi rare-diseas patient doctor
well mobil special salesforc remain
leverag salesforc patient identif
strategi strengthen econom moat
addit strengthen complement franchis
subcutan pipelin therapi
like way
manag recent built pipelin sinc
compani restructur ad sever candid
rare indic high unmet need
exampl compani ad wilson
diseas promis earli data current
phase trial addit candid includ
warm autoimmun hemolyt anemia waiha
gmg light-chain amyloidosi danicopan
pnh extravascular hemolysi
pnh
complement-medi disord sever drug
preclin develop compani
option co-develop commerci elamipretid
mitochondri diseas thank agreement stealth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
osoliri ultomiri orphan drug statu
strong efficaci garner solid price power rare-
payer market share
oalexion abl leverag rare-diseas
expertis infrastructur effici identifi
patient doctor despit small address
olabel expans gener myasthenia gravi
neuromyel optica spectrum disord drive
oa subcutan competitor could reach market
alexion subcutan version take
soliri ultomiri compani key
ofailur quickli convert patient ultomiri
soliri would leav firm vulner competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
compani strong financi health healthi
balanc sheet portfolio drug provid good cash
gener compani issu billion debt
expens synageva acquisit
leisur pay alexion finish fiscal
billion long-term debt time
adjust ebitda estim compani earn
billion cash flow oper next three
year compani histori return cash
sharehold via stock repurchas expect
continu throughout explicit forecast model
unannounc acquisit possibl see
smaller deal next year manag
team see pipelin candid could good fit
compani
mount pressur competitor
biosimilar relianc soliri ultomiri
expect soliri ultomiri make
total revenu highlight compani potenti
concentr risk one key risk impact
competitor biosimilar although soliri closest
pipelin contend early-stag trial lucr
market size rare autoimmun space like
continu attract competit soliri patent
expir biosimilar could enter pnh market around
endang alexion hold indic
growth ultomiri rare indic offset
hit biosimilar forecast alexion face wide
rang possibl outcom long term launch
competitor molecul conveni method
dose could also captur materi portion soliri
market share alexion pois reach market
better version ultomiri less frequent intraven
dose competit well subcutan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
version regulatori failur could provid window
competitor launch subcutan version
alexion robust clinic program expand soliri
effort
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
montreal
fidel manag research compani
share
fund
share
fund
new manag record larg unprov
award alexion standard stewardship rate far
believ outlook promis given recent exampl
strong launch gmg approv ultomiri
pipelin acquisit
alexion histor stewardship turbul
result nearli complet leadership turnov throughout
much spur alleg aggress
sale practic subsequ investig
intern investig board audit financ
committe conclud histor financi statement
need restat howev compani soon
reduct addit chang
silver line improp sale probe
experienc execut baxalta merg
shire current alexion ceo ludwig
hantson led baxalta spin-off baxter
spent year novarti johnson johnson
also includ baxalta novarti addit
prior role neurov cfo aradhana sarin
start medic field work sever
major invest bank serv alexion chief
strategi busi offic john orloff head
research develop year experi
biopharmaceut industri includ role baxalta
baxter merck novarti overal despit everyon
rel new tenur alexion bounti experi
give us confid manag team
well-posit lead compani forward
like way manag taken
initi build pipelin ad candid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
hematolog nephrolog metabol diseas neurolog
cardiolog indic reason acquisit
price collabor term still earli judg
new manag acquisit record acquir
asset treat rare diseas high unmet need line
compani core focu strategi sharp
contrast prior manag decis acquir
synageva billion turn
bad bet difficult-to-diagnos metabol diseas
pipelin candid ultim fail
clinic
develop kanuma come synageva
acquisit provid diversif increment
sale firm came steep price
alexion origin founder retir board
director director appoint
board also boast substanti
experi biopharmaceut industri nine
director independ like ceo
chairman role separ chairman david brennan
good fit given experi ceo astrazeneca
brennan led charg briefli compani
turbul period interim ceo
help secur solid current manag team
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
alexion acquir portola billion deal alexion
attempt expand beyond continu may
may alexion announc agreement acquir
portola deal valu billion buy-out
price per share lofti yet hardli unpreced
premium recent trade level repres
discount portola earli januari share
price look deal think price right
question logic ad portola andexxa
uncontrol bleed alexion portfolio rare-
ultra-rare-diseas drug point expect
materi chang fair valu estim per share
narrow-moat alexion
portola recent suffer tepid sale growth
andexxa
effect certain
anticoagul well failur bevyxxa
anticoagul gain regulatori approv europ
focu improv commerci andexxa
bevyxxa paus pipelin develop
cerdulatinib syk/jak inhibitor certain lymphoma
patient suppos move registr
trial year
first blush see mani synergi unlock
purchas portola andexxa specialti drug
sold hospit typic urgent care set
impli differ commerci strategi
alexion therapi chronic rare diseas alexion
manag team disclos substanti overlap
alexion hospit network portola target
account assuag concern
nonetheless remain skeptic move expect
alexion invest heavili move andexxa forward
addit diversifi alexion revenu
stream expect substanti strengthen
alexion competit posit alreadi
precari posit given competit threat rare-
diseas drug soliri ultomiri
despit question opportun cost deal
alexion plenti dri powder busi develop
size deal seem reason find
andexxa efficaci compel drug avail
revers effect factor xa inhibitor caus
uncontrol life-threaten bleed small portion
roughli patient believ
alexion wing andexxa achiev peak sale
million slightli visibl alpha consensu estim
invest salesforc trial confirmatori
data label expans
anticip mid- high-single-digit decreas
fair valu estim narrow-moat alexion follow
compani fourth-quart result manag
conserv guidanc compani finish year
strong total sale nearli billion
last year adjust oper incom nearli
billion repres margin increas basi point
howev manag conserv top-
bottom-lin guidanc expect
lower growth assumpt rare-diseas drug
soliri ultomiri next year increas
continu believ alexion portfolio well
posit withstand competit pressur eventu
patent expir maintain
narrow moat rate ultomiri crux alexion growth
contribut million fourth quarter
million full year repres solid patient
convers rate older drug soliri within paroxysm
nocturn hemoglobinuria pnh patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
advic hedg fund elliott manag
maintain fair valu estim per share
narrow moat rate alexion
agre elliott manag sentiment alexion
share under-valued stock consist trade
territori howev question merit
push sale point first alexion said
receiv offer date second think
alexion tool increas sharehold valu
could disrupt key compani initi convert
patient ultomiri develop subcutan
inhibitor develop pipelin asset
competit complement-medi diseas mount
time execut crucial alexion maintain
posit market
surpris market inappreci
reaction alexion posit outcom year date
success convers ultomiri well-fortifi
pipelin rel year ago think investor overli
concern competit threat underappreci
alexion first-mov advantag strong cash flow
think sale like time believ long-
term investor consid alexion given current
alreadi switch new drug similar
trend germani japan surpris
manag guidanc combin soliri
ultomiri sale growth year year compar
growth rate given continu ultomiri
convers atyp hemolyt urem syndrom ahu
soliri adopt neurolog indic manag
attribut conserv sale guidanc price
differ ultomiri load start dose versu
mainten dose alreadi model
believ guidanc impli slower-than-expect
convers rate ahu slower-than-expect
neurolog growth given impress execut
ultomiri model sale near
high end manag guidanc watch
complement portfolio perform year unfold
past sever quarter alexion focus build
pipelin new asset expand new rare-
neurolog cardiolog expect sever trial
initi account heighten research
develop guidanc sale adjust
basi expect compar
addit full pipelin new candid compani
invest substanti develop ultomiri next-
gener version includ phase readout
weekli subcutan dose second quarter
launch weekli subcutan inject could fend
sever competitor threaten alexion lead posit
complement-medi diseas next-gen launch
key part thesi
dec alexion issu statement compani
path valu creation indic board
manag team pursu sale contrari
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
